Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Allison M. Marrero"'
Autor:
Adeela Kamal, Ronald Herbst, Robert E. Hollingsworth, David A. Tice, Philip W. Howard, Keven Huang, Mary Jane Hinrichs, Elaine M. Hurt, Haihong Zhong, Marlon Rebelatto, Sanjoo Jalla, Lilian van Vlerken-Ysla, Shannon Breen, Leslie Wetzel, Cui Chen, Linda Xu, Patrick Strout, Martin Korade, Allison M. Marrero, Shenlan Mao, Francois D'Hooge, Ryan Fleming, Jelena Jovanovic, David Bannister, Leeanne Lewis, Rose Marwood, Dorin Toader, Nazzareno Dimasi, Christopher Lloyd, Jay Harper
Supplementary Figure S1. Comparable internalization rates for 5T4_0108 and the 5T4-Tub ADC;Supplementary Figure S2. Affinity optimization improves in vitro cytotoxicity of a 5T4-ADC;Supplementary Figure S3. Induction of apoptosis by 5T4-PBD and 5T4-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de526dbdf0be492e85149344521acac5
https://doi.org/10.1158/1535-7163.22508511
https://doi.org/10.1158/1535-7163.22508511
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Table 1 Pharmacokinetic parametersa of veliparib and its main metabolite (A- 925088) when veliparib was given orally alone on cycle 2 day -1 or in combination with irinotecan on cycle 2 day 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0b2064298c57fd0391eb49d03cd7b2
https://doi.org/10.1158/1078-0432.22457396.v1
https://doi.org/10.1158/1078-0432.22457396.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6dc68fd47e15bb70cf2c00da065fb6
https://doi.org/10.1158/1078-0432.22457402.v1
https://doi.org/10.1158/1078-0432.22457402.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Figure S2. Dose-exposure relationships.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf999e0582e5c5e7ced20ed902272b7
https://doi.org/10.1158/1078-0432.22457411.v1
https://doi.org/10.1158/1078-0432.22457411.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Methods, including numbered supplementary methods figures and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15f8b12093f555d6054157fc56095eec
https://doi.org/10.1158/1078-0432.22457399
https://doi.org/10.1158/1078-0432.22457399
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Table 2 Pharmacokinetic parametersa of irinotecan and its main active metabolite SN-38 when irinotecan was administered as a 1.5-h intravenous infusion (100 mg/m2) alone on cycle 1 day 1 or in combination with veliparib on cycle 2 day 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0655e226af297ffb64a7958454d0e0f
https://doi.org/10.1158/1078-0432.22457393
https://doi.org/10.1158/1078-0432.22457393
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Purpose: PARP is essential for recognition and repair of DNA damage. In preclinical models, PARP inhibitors modulate topoisomerase I inhibitor–mediated DNA damage. This phase I study determined the MTD, dose-limiting toxicities (DLT), pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3571f97af7038b93d2be21fdeace3d90
https://doi.org/10.1158/1078-0432.c.6523568.v1
https://doi.org/10.1158/1078-0432.c.6523568.v1
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Figure S4. Assessment of pNBS1 in the exploratory multiplex immunofluorescence assay.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51aebe132dc65c659c3ef3b27ecd6963
https://doi.org/10.1158/1078-0432.22457405
https://doi.org/10.1158/1078-0432.22457405
Autor:
Geoffrey I. Shapiro, Ralph E. Parchment, Robert J. Kinders, Katherine Ferry-Galow, Jiuping Ji, Yiping Zhang, Allison M. Marrero, Andrew Wolanski, Tracy Bell, Dongpo Cai, Adam Bowditch, Julie L. Boerner, Lawrence Rubinstein, Alice P. Chen, James M. Cleary, Sara M. Tolaney, Jie Zhang, Mary Jo Pilat, Daryn Smith, Scott A. Boerner, Edward A. Sausville, Lance K. Heilbrun, Angelika Burger, Jing Li, Patricia M. LoRusso
Supplementary Figure S3. pNBS1 staining post-combination treatment is limited to tumor cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef94bc03492eefd729eed2abe25a1b8d
https://doi.org/10.1158/1078-0432.22457408.v1
https://doi.org/10.1158/1078-0432.22457408.v1
Autor:
Jiuping J. Ji, Alice P. Chen, Brad A. Gouker, Ralph E. Parchment, Shivaani Kummar, James H. Doroshow, Kristina M. Bigelow, Robert J. Kinders, Katherine V. Ferry-Galow, Scott M. Lawrence, Deborah Wilsker, Donna Butcher, Thomas D. Pfister, William H. Yutzy, Hala R. Makhlouf, Allison M. Marrero
Publikováno v:
Seminars in Oncology. 43:484-491
Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or vari